© 2022 MJH Life Sciences and GeneTherapyLive™. All rights reserved.
© 2022 MJH Life Sciences™ and GeneTherapyLive™. All rights reserved.
January 13, 2022
Genprex will launch the open-label, multicenter, phase 1/2 Acclaim-2 trial in the first quarter of 2022.
November 04, 2021
The FDA also accepted a Type II Variation for the use of tisagenlecleucel in patients with R/R FL following 2 prior lines of treatment.
November 03, 2021
The FDA has pushed cilta-cel's BLA PDUFA date back by almost 4 months.
October 04, 2021
ZUMA-3 showed that a single infusion of the CAR T-cell therapy elicited a high and durable response rate in heavily pretreated patients with relapsed/refractory B-ALL.
October 01, 2021
Treatment with the CAR T-cell therapy yielded a 60% reduction in the risk of EFS events compared with SOC with a median follow-up of 2 years.
September 29, 2021
CT-0508 is currently under investigation in a phase 1 clinical trial.
August 26, 2021
The CAR T therapy tisagenlecleucel missed its EFS endpoint in the phase 3 BELINDA trial for B-cell non-Hodgkin lymphoma.
August 20, 2021
The FDA previously approved ide-cel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma following 4 or more prior lines of therapy.
August 17, 2021
The ongoing phase 1 UNIVERSAL trial has demonstrated an overall response rate of 60% among 10 patients.
July 21, 2021
Findings from an ongoing phase 1 trial were presented at the 2021 ASGCT meeting.